Starpharma Holdings
Starpharma Holdings is an Australian biotechnology company focused on developing dendrimer technology for pharmaceutical and life science applications. Their proprietary dendrimer platform is used to improve drug delivery, enhance drug efficacy, and create new pharmaceutical products. The company's market position is built on its innovative technology and partnerships with pharmaceutical companies.
Short position
Starpharma Holdings (ASX:SPL) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 150,000 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.08 percentage points. Its highest recorded short interest was 5.92% in September 2013. SPL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Starpharma Holdings (SPL) short interest history
SPL Short Interest History
- 30-day change
- -0.00pp
- 90-day change
- -0.08pp
- 1-year change
- -0.08pp
- All-time high
- 5.92% (September 2013)
- All-time low
- 0.00% (November 2010)
Is SPL heavily shorted?
Not especially: 0.03% short interest is modest by ASX standards, ranking #522 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has SPL's short interest changed recently?
Over the past 30 days Starpharma Holdings's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.03% of shares on issue.
What is the highest SPL's short interest has been?
Since 2010, Starpharma Holdings's short interest peaked at 5.92% in September 2013 and bottomed at 0.00% in November 2010.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2010. See our methodology.